Scientific deep-dive
What Is Ecnoglutide? The cAMP-Biased GLP-1 and Its Trial Data
Ecnoglutide is a once-weekly, cAMP-biased GLP-1 drug approved in China. Here is what biased signaling means, what its obesity and diabetes trials found, and why pooled analyses of them disagree.
Ecnoglutide is a once-weekly injectable GLP-1 receptor agonist from Sciwind Biosciences, approved in China for type 2 diabetes in January 2026 and for long-term weight management in March 2026.[6] In its placebo-controlled phase 3 obesity trial, the 2.4 mg dose produced an average 13.2% weight loss at week 40, against a 0.1% change on placebo.[1] Its distinguishing feature is a signaling profile that favors cAMP over β-arrestin, though no trial we read shows that this profile is what produced those results. The phase 3 trials were sponsored by Sciwind and enrolled adults in China.
About this article
This page covers ecnoglutide on its own: mechanism, the diabetes trials and why pooled analyses of them disagree. For how it sits beside survodutide and MariTide, see our three-drug pipeline comparison.
What cAMP-biased means
When a drug activates the GLP-1 receptor, the receptor can signal through more than one route. One runs through the messenger molecule cAMP. Another involves β-arrestin, a protein linked to pulling the receptor inside the cell.[12] The EECOH-2 authors describe ecnoglutide as an agonist that “preferentially activates the cAMP pathway over β-arrestin recruitment.”[3]
The original lab case comes from a 2023 discovery paper written largely by Sciwind employees. In cell assays, ecnoglutide induced cAMP at very low concentrations (EC50 = 0.018 nM) but did not drive receptor internalization (EC50 > 10 μM). In rodent models it led to more weight reduction than semaglutide. A phase 1 study in healthy people found a steady-state half-life of 124 to 138 hours, which supports weekly dosing.[5] Rodent results from a developer’s own paper say little about how the two drugs would compare in patients.
Bias at this receptor is also not unique to ecnoglutide. A 2020 paper, with Eli Lilly employees among its authors, reported that tirzepatide shows bias at the GLP-1 receptor “to favor cAMP generation over β-arrestin recruitment.”[12] So the label describes a lab property shared with at least one drug already on the market.
Sciwind says the mechanism “may explain its enhanced efficacy and sustained metabolic effects.”[7] The trials do not test that claim, and their abstracts show no obvious tolerability edge. In the obesity trial, treatment-emergent adverse events occurred in 93% of each ecnoglutide group and 84% of the placebo group, mostly mild-to-moderate gastrointestinal events, and ten people on ecnoglutide stopped because of adverse events.[1] Against dulaglutide, 3% (0.6 mg) and 4% (1.2 mg) stopped ecnoglutide for adverse events, compared with 3% on dulaglutide, in an open-label trial with HbA1c as its primary endpoint.[3] Neither trial was designed to test bias as a cause of anything.
The phase 3 obesity trial
The trial, which Sciwind calls SLIMMER, randomized 664 adults at 36 centers in China to ecnoglutide 1.2, 1.8 or 2.4 mg or volume-matched placebo once weekly. Participants had a BMI of at least 28, or at least 24 with a weight-related condition, and did not have diabetes. The coprimary endpoints were percentage weight change and the share losing at least 5% at week 40, using the treatment policy estimand, which counts participants’ results regardless of whether they stayed on the drug.[1] Sciwind Biosciences funded it. The week 48 figures below come from a company press release, not from the journal abstract.[7]
| Arm | Week 40 weight change | Difference vs placebo (97% CI) | Lost ≥5% at week 40 | Week 48 weight change (company release) |
|---|---|---|---|---|
| Placebo | +0.1% | n/a | 16% | −0.3% |
| 1.2 mg | −9.1% | −9.2% (−11.0 to −7.5) | 77% | −9.9% |
| 1.8 mg | −10.9% | −11.1% (−13.1 to −9.1) | 84% | −13.3% |
| 2.4 mg | −13.2% | −13.3% (−15.3 to −11.3) | 87% | −15.4% |
You may see a higher headline number. The company reports 15.4% loss at week 48 on 2.4 mg, or 15.1% after subtracting placebo, with 92.8% of that group losing at least 5%.[7] Its announcement of the Pfizer deal repeats the 15.1% figure.[15] Those are later, secondary numbers from a company release rather than the journal abstract, so they should not be set beside another drug’s primary result as if they were equivalent.
How it compares with Wegovy and Zepbound
No head-to-head result has been published, so any comparison is indirect. The largest recent synthesis is a BMJ network meta-analysis of 262 trials. Against lifestyle modification at one year, it reports −14.9% for tirzepatide and −9.8% for subcutaneous semaglutide on moderate to high certainty evidence. It groups ecnoglutide with mazdutide and retatrutide as emerging agents that “may produce similar or greater reductions” of 13.1% to 14.6%, on very low to low certainty evidence.[11] That range covers all three drugs and does not give a figure for ecnoglutide alone. It sits numerically above semaglutide’s estimate, but the certainty ratings are too far apart to treat this as a ranking.
A direct comparison is registered. The study is an open-label, treatment-switching phase 2 trial of ecnoglutide and semaglutide in 163 Chinese adults with a BMI of at least 30 and no diabetes, with percentage weight change at week 48 as its primary outcome and an estimated completion date in August 2027.[16] The registry entry does not list the doses. An unblinded phase 2 study of that size can give the first direct numbers, but it is not built to settle which drug is better.
The type 2 diabetes trials
The diabetes trials tested doses up to 1.2 mg, half the highest dose in the obesity trial. Results come from one phase 2 trial[4] and two phase 3 trials, EECOH-1[2] and EECOH-2[3], all in China and all involving Sciwind funding or staff. The abstracts report least squares or mean changes without naming an estimand, so these figures should not be read as equivalent to the treatment policy result above.
| Trial | Who and how long | Ecnoglutide HbA1c change | Comparator | Difference |
|---|---|---|---|---|
| Phase 2 (Zhu 2024) | 145 adults, 20 weeks | 0.4 mg −1.81%; 0.8 mg −1.90%; 1.2 mg −2.39% | Placebo −0.55% | Not stated in abstract |
| EECOH-1 (Zhu 2026) | 211 adults on diet and exercise or one oral agent, 24 weeks | 0.6 mg −1.96%; 1.2 mg −2.43% | Placebo −0.87% | −1.09% and −1.56% |
| EECOH-2 (He 2025) | 621 adults on metformin, week 32 of 52, open label | 0.6 mg −1.91%; 1.2 mg −1.89% | Dulaglutide 1.5 mg −1.65% | −0.26% and −0.24% |
EECOH-2 is the most informative of the three because it used an active drug. Both doses were non-inferior to dulaglutide, the older weekly GLP-1 covered in our Trulicity alternatives guide. The 1.2 mg dose also met the test for superiority, but the authors wrote that the difference “was not considered clinically relevant.”[3] In the phase 2 trial, 71.9% of the 1.2 mg group reached an HbA1c of 6.5% or lower, compared with 9.1% on placebo, and 33.3% lost at least 5% of body weight, compared with 3.0%.[4]
Why the meta-analyses disagree
Three systematic reviews published in 2026 pooled the diabetes evidence and came out with quite different numbers.[8][9][10] Their HbA1c estimates differ about threefold, and they also disagree on dose response: one found “a clear dose-dependent relationship” for HbA1c, while another said its exploratory subgroups “did not establish a clear dose response relationship.”[8][10]
| Review | Trials and people | Pooled HbA1c difference | Pooled weight difference | Adverse events |
|---|---|---|---|---|
| Feng (Front Endocrinol) | 3 RCTs, 977 | −1.40 vs placebo; −0.24 vs dulaglutide | −2.16 vs placebo | OR 2.03 for any event; serious events not different |
| Kumar (Endocrinol Diabetes Metab) | 4 RCTs, 1,643, including the SLIMMER obesity trial of people without diabetes | −0.44 | −5.63 | RR 1.09; serious events not different |
| Abunada (Diabetol Metab Syndr) | 3 RCTs, 979 | −0.57% | −1.83 kg | More frequent, not significant; no rise in serious events |
The likeliest reason for the HbA1c gap is the comparator. Feng’s full text reports the two kinds of trial separately: −1.40 against placebo and −0.24 against dulaglutide. The other two reviews pooled placebo and active comparators into one estimate, and the individual trials show the same far smaller gap against dulaglutide.[2][3][8][9][10] Kumar’s larger weight figure also has a likely explanation: its four trials include the SLIMMER obesity trial, which enrolled people without diabetes at doses up to 2.4 mg, and its authors report that heterogeneity in weight measures fell substantially without that trial.[1][9] With three or four trials, one inclusion decision can move an estimate a long way. The individual trials in the table above are easier to interpret than any of these pooled figures. Feng’s authors themselves say the evidence “remains limited.”[8]
Drug interaction studies
Slowed gastric emptying is why GLP-1 drugs get checked against common oral medicines. Two small open-label phase 1 studies, each with 28 healthy volunteers and Sciwind employees among the authors, looked at this. With steady-state ecnoglutide 1.2 mg, total exposure was 106% (90% CI 94% to 120%) of the level without ecnoglutide for rosuvastatin and 84% (76% to 94%) for digoxin. The authors concluded no dose change was needed but advised close monitoring with digoxin, especially in kidney impairment.[13] A second study found total exposure to metformin and warfarin met its no-effect criteria, with modest drops in peak levels and no clinically relevant INR change.[14] Healthy-volunteer studies do not replace monitoring in patients.
Where it is available and what comes next
Both approvals described in the 2026 Drugs review are Chinese. The same review says ecnoglutide is being studied in adolescents with obesity and in adults with obesity plus sleep apnea or knee osteoarthritis, and that an oral tablet is in clinical development.[6] Under a February 2026 agreement, Pfizer holds exclusive commercialization rights in Mainland China, while Sciwind stays the marketing authorization holder.[15] This is the same position as mazdutide, another incretin drug approved in China and not in the US.
DailyMed, the NIH database of US drug labels, returned no ecnoglutide label in November 2026.[18] The oral form, called VRB-101, is the part of the program being tested in the US. Verdiva Bio’s EVOLVE-2 is a placebo-controlled phase 2b trial with five active arms, over 200 participants at 22 US sites and 20 weeks of once-weekly dosing; in February 2026 the company said it expected topline data by the end of that year.[17] A phase 2b dose-finding study of a pill does not tell us how the injected drug would perform in US patients, and the injectable phase 3 data have no US participants to draw on.[1][2][3]
If you see ecnoglutide sold online
A product marketed in the US as ecnoglutide would not be an FDA-approved drug, and nothing in these trials tells you what is in it. If you are interested in a weekly GLP-1, the useful conversation with a prescriber is about the options that have US labels, how they fit your health history, and whether a clinical trial is an option for you.
Frequently Asked Questions
References
- 1.Ji L, Gao L, Xue H, et al. Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2025. PMID: 40555243.
- 2.Zhu D, Wang W, Tong G, et al. Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial. Nat Commun. 2026. PMID: 41501026.
- 3.He Y, Mi N, Cheng Z, et al. Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2025. PMID: 40854315.
- 4.Zhu D, Wang W, Tong G, et al. Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial. Nat Commun. 2024. PMID: 39333121.
- 5.Guo W, Xu Z, Zou H, et al. Discovery of ecnoglutide - A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog. Mol Metab. 2023. PMID: 37364710.
- 6.Shirley M. Ecnoglutide: First Approvals. Drugs. 2026. PMID: 42412371.
- 7.Sciwind Biosciences. Sciwind Biosciences Announces Publication of Phase III SLIMMER Trial Results in The Lancet Diabetes & Endocrinology and Oral Presentation at ADA Scientific Sessions (company press release). BioPharma Dive press release page. 2025. https://www.biopharmadive.com/press-release/20250621-sciwind-biosciences-announces-publication-of-phase-iii-slimmer-trial-result-1/
- 8.Feng Y, Sun C, Li X, et al. Dose-response and time-course effects of ecnoglutide in type 2 diabetes: a systematic review and meta-analysis of efficacy. Front Endocrinol (Lausanne). 2026. PMID: 42798476.
- 9.Kumar M, Kumar S, Ali SME, et al. Comparative Efficacy and Safety of Ecnoglutide in Type 2 Diabetes: A Systematic Review and Meta-Analysis. Endocrinol Diabetes Metab. 2026. PMID: 41937314.
- 10.Abunada S, Abunada O, Vivek F, et al. Evaluating the therapeutic benefits and safety of ecnoglutide for type 2 diabetes: evidence from a systematic review and meta-analysis. Diabetol Metab Syndr. 2026. PMID: 42908033.
- 11.Nong K, Shi Q, Xie X, et al. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. BMJ. 2026. PMID: 42419792.
- 12.Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020. PMID: 32730231.
- 13.Li F, Du C, Yu Q, et al. Effect of a Novel GLP-1 Analogue Ecnoglutide on the Pharmacokinetics of Rosuvastatin and Digoxin in Healthy Participants. Diabetes Obes Metab. 2026. PMID: 42310888.
- 14.Chen Z, Du C, Cai L, et al. No dose adjustment required for warfarin or metformin when coadministered with the novel GLP-1 receptor agonist ecnoglutide: an open-label, fixed-sequence, crossover study. Front Pharmacol. 2026. PMID: 42137314.
- 15.Sciwind Biosciences. Sciwind Biosciences Partners with Pfizer China to Commercialize its Biased GLP-1 in China (company press release). BioSpace press release page. 2026. https://www.biospace.com/press-releases/sciwind-biosciences-partners-with-pfizer-china-to-commercialize-its-biased-glp-1-in-china
- 16.Hangzhou Sciwind Biosciences Co., Ltd. A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH). NCT07073417. ClinicalTrials.gov. 2025. https://clinicaltrials.gov/study/NCT07073417
- 17.Verdiva Bio. Verdiva Bio Announces Completion of Enrollment for EVOLVE-2 Phase 2b Study of VRB-101, a Potential Once-Weekly Oral GLP-1 Peptide Analog in Individuals with Obesity (company press release). BioSpace press release page. 2026. https://www.biospace.com/press-releases/verdiva-bio-announces-completion-of-enrollment-for-evolve-2-phase-2b-study-of-vrb-101-a-potential-once-weekly-oral-glp-1-peptide-analog-in-individuals-with-obesity
- 18.National Library of Medicine. DailyMed search results for ecnoglutide. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=ecnoglutide
Related research
The Next GLP-1 Pills: Elecoglipron, Aleniglipron and Other Oral Drugs in Trials
A wave of daily small-molecule GLP-1 pills is moving through trials after Foundayo and the Wegovy pill. What 2026 trials of elecoglipron, aleniglipron, safiglipron (HRS-7535), VCT220 and TERN-601 showed, why TERN-601 was dropped, and why none is available yet.
8 min read
Zenagamtide Pill vs Shot: What the Phase 2 Lancet Reports Found
Two Lancet reports tested daily oral and weekly injected zenagamtide (amycretin) in type 2 diabetes. Here is how HbA1c, company-reported weight loss and side effects compare, and why the comparison is still indirect.
7 min read
Mazdutide vs Dulaglutide in Type 2 Diabetes: The Nature Trials
In the phase 3 DREAMS-2 trial, mazdutide beat dulaglutide 1.5 mg on HbA1c and weight at 28 weeks in Chinese adults. Here is what the gap means, why the figures vary, and what the trials leave open on higher dulaglutide doses and heart outcomes.
8 min read
ACHIEVE: Oral Orforglipron in Type 2 Diabetes (2026)
The oral orforglipron T2D phase 3 program (ACHIEVE, often searched as QWINT): HbA1c and weight results across five trials, the head-to-head win over oral semaglutide, and safety.
13 min read
Orforglipron and the Heart: The Lancet Cardiovascular Safety Trial
ACHIEVE-4 found orforglipron non-inferior to insulin glargine for major cardiovascular events in high-risk adults with type 2 diabetes. What the result shows, what it leaves open, and how far it applies to people taking Foundayo for weight.
8 min read
Retatrutide vs Ozempic: T2D Phase 2 Cross-Trial Evidence (vs SUSTAIN-7)
Indirect T2D comparison: retatrutide 12 mg -2.02% HbA1c (phase 2) and -18.8% body weight at 80 wk (TRIUMPH-2, placebo-controlled) vs Ozempic 1.0 mg -1.8% HbA1c / -6.5 kg (SUSTAIN-7). Ozempic FDA-approved 2017; retatrutide investigational.
12 min read
Where to get GLP-1 safely: vetted online providers
Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.
No insurance needed · vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
Ro
FDA-approved brand GLP-1s, including the Wegovy pill and Foundayo, with insurance help
Read full review →From $149/mo
+ required membership
Collective
The lowest flat medication price if you can absorb an annual membership fee
Read full review →From $59/mo
+ required membership
CoreAge Rx
Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose
Read full review →From $79/mo
“starting at” price